News & Videos - VIVORYON

Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 Halle (Saale) / Munich, Germany, April 16, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its financial results for the full year 2023 and...

Vivoryon Therapeutics N.V. Announces Changes to Board Composition Halle (Saale) / Munich, Germany, March 15, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced changes among the Non-Executive members of its Board of Directors. Professor Morten Asser Karsdal, MSc, PhD, mMBA...

Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer ’ s Disease VIVIAD Phase 2b study did not meet its primary and key secondary endpoints Varoglutamstat was generally well tolerated with low discontinuation rates due to adverse events and no evidence of symptomatic ARIAs in the clinical setting VIVIAD is a comprehensive, diligently designed and high-quality study; baseline demographics in the study were highly representative of early AD...

Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024 Halle (Saale) / Munich, Germany, January 8, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that members of its management team including CEO Frank Weber, MD, CBO Michael Schaeffer, PhD, and CS & IRO Anne...

Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress VIVIAD and VIVA-MIND studies both advancing as planned at 600mg twice daily following positive DSMB decisions; VIVIAD safety update with cut-off as of November 20, 2023, confirms low level of discontinuations On track to report VIVIAD final topline Phase 2b data during end of Q1/2024 Commenced preparations for VIVALONG, an open-label extension study Unveiling focused growth strategy...

Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023 Halle (Saale) / Munich, Germany, November 28, 2023 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its third quarter financial results for the period...

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference Halle (Saale) / Munich, Germany, November 7, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company’s management will present at the following conference: Jefferies London Healthcare...

Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision Both VIVIAD and VIVA-MIND progressing at 600mg twice daily with oral administration following two independent positive DSMB decisions Varoglutamstat demonstrates very encouraging safety data with no evidence of drug-related ARIAs at therapeutic dose of 600mg twice daily, a dose demonstrated to result in nearly 90% target occupancy On...

Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose Interim analysis completed, with 600mg twice daily dosing unanimously selected by independent DSMB as final dose for remainder of Phases 2a and 2b of VIVA-MIND study in U.S. Decision follows 2022 DSMB determination for VIVIAD Phase 2 EU study to proceed at 600mg twice...

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders Multiple KOLs highlight varoglutamstat pathology, clinical development and clinical applicability of key endpoints in VIVIAD study VIVIAD progressing as planned with final results expected Q1/2024 Halle (Saale) / Munich, Germany, October 17, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small...

Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation Halle (Saale) / Munich, Germany, October 5, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced its plans to host a Virtual R&D Event with Key Opinion Leaders...

Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board Halle (Saale) / Munich, Germany, September 15 , 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon , or the Company ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, held its Extraordinary General Meeting (EGM) today at 1:00...

Vivoryon Therapeutics N.V. Reports H1 202 3 Financial Results and Highlights Operational Progress Both VIVIAD and VIVA-MIND studies on track; final data from VIVIAD expected in Q 1/ 2024 , and a study update on VIVA-MIND expected in Q 4/ 2023 Varoglutamstat demonstrate s very encouraging safety data with no drug-related ARIA s at therapeutic dose of 600 mg twice daily, a dose demonstrated to result in nearly 90% target occupancy DSMB meeting results support current protocol for VIVIAD and...

Vivoryon Therapeutics N.V. t o Report Half Year 202 3 Financial Results and Operational Progress on September 07 , 202 3 Halle (Saale) / Munich, Germany , August 31 , 202 3 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its financial results for the half...

Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board , Being H eld on September 15, 2023 Halle (Saale) / Munich, Germany, August 4 , 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon , or the Company ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it...

Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer Frank Weber, MD, current Chief Medical Officer (CMO) , promoted to Chief Executive Officer (CEO) to lead Company through next stage of development with focus on upcoming VIVIAD trial readout in 1Q24 To-Date, varoglutamstat has demonstrated potential for meaningful safety and ease of use advantages over antibody-based therapies, continues to show encouraging safety data at therapeutic dose of...

Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease Small molecule varoglutamstat, with potential for meaningful safety and ease of use advantages over antibody-based therapies, continues to show encouraging safety data at t herapeutic dose of 600 mg twice daily , a dose demonstrated to result in nearly 90% target occupancy VIVIAD data presented at AAIC 2023 demonstrate that WAIS-IV...

Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting All p roposed r esolutions a pproved Election of two new Non- Executive Board member s Halle (Saale) / Munich, Germany , June 2 1 , 202 3 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced the appointment of...

Vivoryon Therapeutics N.V. Announces CEO Transition Plan Dr. Ulrich Dauer not to extend current term running through 2024 AGM Board to i nitiate s uccession p lanning Halle (Saale) / Munich, Germany , June 15 , 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the...

Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences Halle (Saale) / Munich, Germany, June 1 , 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company’s management will participate in the following conferences: BIO International Convention ( June 5-...